CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 74 enrolled
Drug / intervention
Intravaneous iron(low molecular weight iron dextran)drug
Likely dose
Intravaneous iron(low molecular weight iron dextran) 1000 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02038023
NCT02038023Phase 2Completed
CompareCT.gov

Intravaneous Iron(1000 mg Low Molecular Weight Iron Dextran Over 60 Minutes) for Moderate to Severe Iron Deficient Anemia of Pregnancy in Women Intolerant of or Responsive to Oral Iron.

Auerbach Hematology Oncology Associates P C·interventional·Posted Jan 16, 2014·Updated Jun 28, 2018

In Brief

A Phase 2 clinical trial evaluating Intravaneous iron(low molecular weight iron dextran) for Pregnancy. Completed, enrolled 74 participants across 1 site.

Detailed Summary

To determine the percentage of women who achieve anemia correction after a single dose of 1000mg of low molecular weight iron dextran(infed).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPregnancy
CountriesUnited States
CollaboratorsPharmacosmos A/S

Timeline

Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJan 16, 2014
Enrollment StartJul 1, 2013
Primary CompletionJul 1, 2015
Study CompletionAug 1, 2015
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 12.5 years ago

Interventions

Intravaneous iron(low molecular weight iron dextran)drug

1000 mg of Iron dextran administered over one hour